key: cord-0716186-49ooaiae
authors: Leng, Yan; Chen, Ming; Dai, Mengyuan; Wu, Yang; Lei, Shao‐qing; Yan, Kuo; Shao, Ning‐Yi; Xia, Zhongyuan; Liu, Miao
title: Minimize glycemic fluctuation decrease the risk of severe illness and death in patients with COVID‐19
date: 2020-10-07
journal: J Med Virol
DOI: 10.1002/jmv.26584
sha: 728b3e9a5eb8d152c758216e01c2aaf4039cb297
doc_id: 716186
cord_uid: 49ooaiae

The recent coronavirus disease (COVID‐19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) and has been spreading rapidly throughout the continents. The insights in how this viral disease affects general population is thus urgently needed. Diabetes mellitus is one of the leading threats for morbidity and mortality globally. Infection of coronavirus in diabetic patients may trigger acute hyperglycemia due to increased secretion of hyperglycemic hormones, extensive application of glucocorticoids to patients with severe symptoms and the potential pathogenicity of coronavirus in pancreas expressing angiotensin‐converting enzyme 2 (ACE2) This article is protected by copyright. All rights reserved.

The recent coronavirus disease (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and has been spreading rapidly throughout the continents. The insights in how this viral disease affects general population is thus urgently needed. Diabetes mellitus is one of the leading threats for morbidity and mortality globally. Infection of coronavirus in diabetic patients may trigger acute hyperglycemia due to increased secretion of This article is protected by copyright. All rights reserved.

hyperglycemic hormones, extensive application of glucocorticoids to patients with severe symptoms and the potential pathogenicity of coronavirus in pancreas expressing angiotensin-converting enzyme 2 (ACE2) [1] . Acute fluctuations of glucose exert more deleterious effects on diabetes progression than sustained hyperglycemia. In this regard, the third metric of glucose control, known as glycemic variability, has been confirmed to be a strong predictor of in-hospital mortality [2] . Glucose management of diabetic patients carrying COVID-19 poses challenges to physicians, including identifying blood glucose targets, judicious use of oral diabetes mellitus medications and insulin administration. However, the information on epidemiological and glycemic control of diabetic patients, who has contracted this highly communicable disease, is still limited to date. Here we performed a retrospective comparative study enrolling 800 COVID-19 patients (with or without diabetes) who discharged or died between February 1st and March 30th, 2020. These patients were enrolled from two government-designated hospitals for COVID-19 patients in Wuhan, China. We analyzed the risk of severe clinical outcomes (death, ICU administration, invasive mechanical ventilation, severe or critical symptoms) among these patients after being infected with SARS-CoV-2 and investigated the short-term impact of glycemic control on The adjusted odds ratio (aOR) in Table 1reveals that diabetes increases the risk of severe outcomes to approx. 2.74 times after unbiased adjustment of age/sex and other comorbidities. The cumulative incidence curves ( Figure 1) show that the COVID-19 patients with diabetes deteriorate more rapidly than those without diabetes. (Hazard ratio 3.13; 95% CI 1.85 -5.27; P<0.01).

We next calculated the standard deviation (Glu SD ), average blood glucose (Glu Ave ) and maximal blood glucose (Glu Max ) of COVID-19 patients with diabetes during hospitalization. Using multivariate logistic regression analysis, we have observed that Glu SD , a parameter commonly used to describe variability of blood glucose, is significantly associated with severe outcomes in diabetic COVID-19 This article is protected by copyright. All rights reserved. (Table 1) .

It has been reported that lowering blood glucose concentration may improve the critical symptoms of COVID-19 patients with diabetes [3] . However, blood glucose concentrations in COVID-19 patients with diabetes often undergo substantial fluctuation due to extensive application of glucocorticoids and potential damage of SARS-CoV-2 to pancreas, which may invite more adverse effects than sustained hyperglycemia [4] . In these patients, the Glu SD is therefore a significant predictor of severe outcomes during hospitalization and its predictive ability is greater than that of Glu Adm , Glu Max and Glu Ave . In our research, some results showed a significant P-value (P<0.05, or P<0.01) with the confident intervals cover 1 (Table 1) , which may be related with our relatively small population involved in this study. Further studies with a larger sample size may improve the significance of the study. Our findings suggest that to minimize glycemic fluctuation should be an important dimension of glycemic control for COVID-19 patients with diabetes. It might not be necessary to keep pursuit of This article is protected by copyright. All rights reserved.

lower glucose levels with the attendant risk of hypoglycemia or a protocol requiring frequent and accurate glucose measurements, however, it is notable to avoid large glucose fluctuation for these patients during hospitalization.

Data are aOR (95% CI, P value). aOR estimated by logistic regression. *Model 1: The results were adjusted for age and sex. † Model 2: The results were adjusted for age, sex, other comorbidities including hypertension, chronic pulmonary disease, chronic cardiac disease, cerebrovascular disease, renal insufficiency, hypohepatia. + : Significant P-value estimated by logistic regression. ++ : Significant adjusted P-value after Bonferroni correction. 

Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes

The impact of glycemic variability on length of stay and mortality in diabetic patients admitted with communityacquired pneumonia or chronic obstructive pulmonary disease

Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes

Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes